Yes, artificial intelligence can meaningfully improve regulatory submission accuracy. AI tools are particularly effective at catching formatting inconsistencies, missing cross-references, and terminology mismatches that human reviewers often overlook under time pressure. The sections below unpack exactly how AI helps, where it falls short, and what regulators currently think about its use in regulatory submissions.
What types of regulatory submission errors does AI actually catch?
AI is most effective at catching structural and consistency errors in regulatory submissions. These include mismatched cross-references between modules, incorrect section numbering, terminology inconsistencies across documents, missing required fields, and formatting deviations from agency-specific templates such as eCTD requirements. These are errors that are easy to miss in large dossiers but straightforward for AI to detect systematically.
Beyond formatting, AI tools trained on regulatory language can flag ambiguous or contradictory statements in clinical summaries, CMC sections, and labeling. For example, if a product’s shelf life is stated differently in two separate modules, an AI system can surface that discrepancy before submission. The same applies to unit inconsistencies, undefined abbreviations, and references to outdated guideline versions.
What AI does not reliably catch are scientific judgment errors. If the data interpretation in a clinical overview is flawed, or if a regulatory strategy is built on a misreading of agency expectations, AI tools generally lack the domain depth to flag those issues. That remains the domain of experienced regulatory professionals.
How does AI process and review regulatory documents?
AI processes regulatory documents primarily through natural language processing (NLP) and machine learning models trained on large volumes of regulatory text. The system parses document content, compares it against predefined rules or learned patterns, and flags deviations. Some tools also use optical character recognition (OCR) to handle scanned documents and convert them into machine-readable text for analysis.
In practice, most AI review tools work in layers. A rules-based layer checks for compliance with fixed requirements, such as eCTD structure or mandatory section headings. A machine learning layer then identifies patterns that correlate with agency feedback or rejection, based on historical submission data. More advanced systems use large language models to assess narrative coherence and cross-document consistency at a deeper level.
The output is typically a structured report listing flagged issues by section, severity, and type. Regulatory teams then review these flags and decide which require action. AI does not make submission decisions; it surfaces information to help humans make better ones.
What are the limitations of AI in regulatory submissions?
The core limitation of AI in regulatory submissions is that it cannot exercise scientific or strategic judgment. AI can confirm that a section exists and that its formatting is correct, but it cannot evaluate whether the clinical evidence is sufficient to support the proposed indication or whether the regulatory strategy aligns with current agency thinking. Those assessments require human expertise and contextual knowledge.
Additional limitations include:
- Training data gaps: AI models are only as good as the data they were trained on. If training data does not reflect recent guideline updates or region-specific requirements, the tool may miss important compliance issues.
- Language and nuance: Regulatory documents often contain nuanced scientific language where small wording differences carry significant meaning. AI can misinterpret or overlook these distinctions.
- Overconfidence risk: Teams that rely too heavily on AI review may develop a false sense of security, assuming that a clean AI report means a submission is ready. It does not.
- Novel product types: For complex products such as ATMPs, combination products, or first-in-class biologics, AI tools trained on conventional submissions may not apply appropriate standards.
Used as one layer of a broader quality control process, AI adds real value. Used as a substitute for expert review, it introduces risk.
Which regulatory submission tasks are best suited for AI automation?
The regulatory submission tasks best suited for AI automation are repetitive, rule-based, and high-volume. These are tasks where consistency matters more than judgment, and where human error rates tend to increase with fatigue or document volume.
Tasks that AI handles well include:
- eCTD structure validation and hyperlink checking
- Cross-reference verification across modules
- Terminology and abbreviation consistency checks
- Labeling compliance review against template requirements
- Translation quality screening for multilingual submissions
- Document version control and change tracking
- Automated formatting of tables and appendices to agency specifications
Tasks that still require human expertise include scientific narrative writing, benefit-risk assessment, regulatory strategy development, agency meeting preparation, and responses to questions from health authorities. These involve interpretation, relationship management, and professional judgment that AI cannot replicate.
A practical approach is to use AI to handle the mechanical layer of submission preparation, freeing regulatory professionals to focus on the strategic and scientific work that drives approval outcomes. For teams managing regulatory submissions across multiple markets simultaneously, this division of labor can significantly improve both speed and quality.
How do regulatory agencies view AI-assisted submissions?
Regulatory agencies including the EMA, FDA, and MHRA have all begun engaging seriously with AI in regulatory contexts, but none currently require or prohibit its use in submission preparation. The prevailing agency position as of 2026 is one of cautious openness: agencies are open to AI-assisted submissions but expect the applicant to remain fully accountable for all content, regardless of how it was produced or reviewed.
The EMA has published reflection papers on the use of AI in medicines development and is actively monitoring how AI tools are being applied across the product lifecycle. The FDA has similarly issued guidance on AI in drug development and is developing frameworks for evaluating AI-generated evidence. Both agencies emphasize that AI does not change the standards for submission quality or scientific rigor.
From a practical standpoint, agencies are not currently asking applicants to disclose whether AI tools were used in document preparation or review. However, this may evolve. Some agencies are beginning to ask about AI use in specific contexts, particularly where AI-generated content could affect data integrity or scientific conclusions.
The safest approach is to treat AI as a quality tool within a validated process, document its use internally, and ensure that qualified human reviewers take responsibility for every submission. Learn more about our approach to compliance and quality on our company page.
How Starodub supports accurate regulatory submissions
We work with biopharmaceutical and medical device companies to prepare, review, and submit regulatory dossiers that meet the standards of the EMA, FDA, and other health authorities. Our team combines regulatory expertise with structured quality processes to reduce submission errors and improve first-cycle approval rates.
Here is how we help:
- Dossier preparation and review: We prepare and critically review CTD modules, eCTD packages, and supporting documentation for small molecules, biologics, vaccines, and medical devices.
- Consistency and compliance checks: Our review process includes systematic cross-document checks that catch the types of errors AI tools are designed to flag, combined with expert judgment on scientific and strategic content.
- Regulatory strategy: We advise on submission pathways, agency interactions, and classification strategies to ensure your dossier is built on a sound regulatory foundation from the start.
- Quality and compliance support: Through our Quality, Compliance, and Operational Improvements division, we help teams build internal processes that reduce errors before they reach the submission stage.
- Multi-market submissions: We manage submissions across the EU, the US, and other markets, ensuring regional requirements are met without duplicating effort.
If you want to reduce submission errors and move through regulatory review with greater confidence, we would be glad to discuss your project. Get in touch with our team to explore how we can support your next submission.
Related Articles
- What is regulatory strategy validation and why does it matter?
- How do FDA and EU MDR requirements differ?
- How do breakthrough device designations accelerate regulatory approval?
- How does software as medical device (SaMD) regulation work?
- How do you determine medical device classification?
This content was generated with the help of AI and it may contain mistakes